Figure 6.

Effect of therapeutic vaccination route on tumor growth. We compared the efficacy of two doses of therapeutic vaccination on control of B16.ova melanoma growth. Mice were inoculated with tumor cells on the right flanks. 9–10 days later injected via different routes with high dose 0,172 mg of PLGA nanoparticles (containing 6ug Ovalbumin and 28ng IMM60) (a, b), or low dose 0.0172 mg PLGA nanoparticles (containing 0.6ug Ovalbumin and 2.8ng IMM60) (c, d, e). Subcutaneous and intranodal vaccinations were performed on the same side of the animal as the tumors inoculated. (a) Tumor growth and survival curves of high dose treatment are shown. Log-rank (Mantel-Cox) test was used to compare survival curves. (b) 24-hour serum IFN levels and endpoint serum anti-ovalbumin IgG2 c levels of high dose treatment in A were shown. One-way ANOVA was used for comparisons. N = 6 mice per group (c, d) As in A and B but a low dose of particles was used. N = 6 mice per group. (e) As in C, a low dose of particles was introduced via intravenous or intranodal routes on day 9 after tumor inoculation. Some mice received anti-PD-1 antibodies intraperitoneally starting on day 9 before particle injections and repeated every 3 days for 2 weeks. N = 5 mice per group. Log-rank (Mantel-Cox) test was used to compare survival curves